Clinical Outcomes Research
Our unique position in the outpatient infusion management setting, in collaboration with our physician partners, gives us unprecedented access to the highest quality real-world clinical data.
Our data warehouse is the largest in the outpatient infusion industry
Our data sets go way beyond simple claims data and provide evidence-based research in areas such as drug utilization, clinical outcomes and disease response, safety, health economic impacts, and persistence. The strength of our data allows us to collaborate with manufacturers and physicians to study novel therapies, compare treatment sites, and other cutting-edge research.
Clinical Outcomes
Cost Savings & Lower Resource Utilization
New Therapies and Programs
Persistance
Special Populations
Here is an example of one of our class-leading studies enabled by our data:
Click image to view full size
Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin, PharmD - Healix Infusion Therapy, Sugar Land, TX Claudia P. Schroeder, PharmD, PhD - Healix Infusion Therapy, Sugar Land, TX View Poster
All Categories
Real-World Experience with Microbiota Treatment for the Prevention of Recurrent Clostridioides difficile Infection
Real-World Experience with Microbiota Treatment for the Prevention of Recurrent Clostridioides difficile Infection
Presented at ACG 2024 Authors: Timothy E. Ritter, MD Jonathan A. Rosenberg, MD Richard L. Hengel MD Sujatha Krishan, MD Kathy A. Baker Ph.D., APRN Lucinda J. Van Anglen, PharmD Kelly E. Hanna, PharmD Amy Guo, PhD Mielad Moosapanah, PharmD Sanghyuk Seo, PharmD, MS...
A 3-Year Evaluation of Antibiotic Resistance Patterns in Gram-Negative Genitourinary Tract Infections Treated in Outpatient Infusion Centers (POICs)
A 3-Year Evaluation of Antibiotic Resistance Patterns in Gram-Negative Genitourinary Tract Infections Treated in Outpatient Infusion Centers (POICs)
Published December 4, 2021 Richard L. Hengel, MD Brian S. Metzger, MD, MPH H. Barry Baker, MD, FACP John S. Adams, MD Ramesh V. Nathan, MD, FIDSA Rishi Bhattacharyya, MD Richard M. Mandel, MD, FIDSA Kimberly A. Couch, PharmD, MA, FIDSA, FASHP Claudia P. Schroeder,...
Successful Early Discharge and Avoided Hospitalization for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Treated with Outpatient Parenteral Antimicrobial Therapy (OPAT) Result in Healthcare Cost Savings
Successful Early Discharge and Avoided Hospitalization for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Treated with Outpatient Parenteral Antimicrobial Therapy (OPAT) Result in Healthcare Cost Savings
Presented on October 24, 2016 Robin H. Dretler, MD, FIDSA - Infectious Disease Specialists of Atlanta, PC, Decatur, GA Quyen Luu, MD, Macon, GA Richard C. Prokesch, MD, FACP, FIDSA - Infectious Diseases Associates, Riverdale, GA Andrew H. Krinsky, MD - Infectious...
A 2-Year Analysis of 30-Day Hospital Readmissions and Cost Benefits of Septicemia Outpatient Treatment in a Physician Office Infusion Center (POIC)
A 2-Year Analysis of 30-Day Hospital Readmissions and Cost Benefits of Septicemia Outpatient Treatment in a Physician Office Infusion Center (POIC)
Presented on October 7, 2015 Barry Statner, MD, CM FRCPC, FIDSA Fernando S. Alvarado, MD, MPH, TM Brian Metzger, MD, MPH Richard M. Mandel, MD, FIDSA Jorge R. Bernett, MD H. Barry Baker, MD, FACP Alfred E. Bacon III, MD Claudia P. Schroeder, PharmD, PhD Lucinda J....
Comparison of Outpatient Antimicrobial Therapy (OPAT) in a Physician Office Infusion Center (POIC) vs. Traditional Home Health Care (HHC)
Comparison of Outpatient Antimicrobial Therapy (OPAT) in a Physician Office Infusion Center (POIC) vs. Traditional Home Health Care (HHC)
Presented on October 8, 2014 Richard C. Prokesch, MD, FACP, FIDSA -Infectious Disease Associates, Riverdale, GA John S. Adams, MD, FIDSA -Knoxville Infectious Disease Consultants, PC, Knoxville, TN Ramesh V. Nathan, MD- Mazur, Statner, Dutta, Nathan, PC, Thousand...
Cost Savings Utilizing Outpatient Parenteral Antimicrobial Therapy (OPAT) for Treatment of Complicated Skin and Skin Structure Infections (cSSSI) in Physician Operated Infusion Centers (POICs) without Hospitalization
Cost Savings Utilizing Outpatient Parenteral Antimicrobial Therapy (OPAT) for Treatment of Complicated Skin and Skin Structure Infections (cSSSI) in Physician Operated Infusion Centers (POICs) without Hospitalization
Presented on October 27, 2009 Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Inc, Sugar Land, TX Michael P. Dailey, MD - Infectious Disease Services of GA, Roswell, GA Andrew H. Krinsky, MD - Infectious Disease Associates, Sarasota, FL John S. Adams, MD -...
Publication: Outpatient Treatment of Osteomyelitis with Telavancin
Publication: Outpatient Treatment of Osteomyelitis with Telavancin
Published July 2017 Claudia P. Schroeder, PharmD, PhD Lucinda J. Van Anglen, PharmD Robin H. Dretler, MD John S. Adams, MD, FIDSA, FSHEA Richard C. Prokesch, MD, FACP, FIDSA Quyen Luu, MD Andrew H. Krinsky, MD View...
Outpatient Treatment of Infective Endocarditis at Physician Office Infusion Centers (POICs): A 2-Year Analysis of Clinical and Economic Outcomes
Outpatient Treatment of Infective Endocarditis at Physician Office Infusion Centers (POICs): A 2-Year Analysis of Clinical and Economic Outcomes
Presented on October 24, 2016 Brian S. Metzger, MD, MPH Richard M. Mandel, MD, FIDSA Jorge R. Bernett, MD Barry Statner, MD, FRCPC, FIDSA John S. Adams, MD, FIDSA, FSHEA Alfred E. Bacon, III, MD Kimberly Couch, PharmD, MA, FIDSA, FASHP Claudia P. Schroeder, PharmD,...
Real-World Comparison of Arthralgias with Infliximab vs. Vedolizumab in the Treatment of Bio-Naïve Inflammatory Bowel Disease
Real-World Comparison of Arthralgias with Infliximab vs. Vedolizumab in the Treatment of Bio-Naïve Inflammatory Bowel Disease
Selected as a Poster of Distinction Presented on January 23, 2020 Authors: Timothy E. Ritter, MD - GI Alliance, Southlake, TX Chris Fourment, MD - GI Alliance, Southlake, TX Samantha A. Mehta, PharmD - Healix Infusion Therapy, Sugar Land, TX Lucinda J. Van Anglen,...
Outpatient Treatment and Recurrence of Prosthetic Joint Infection (PJI) Treated in Infectious Disease (ID) Physician Office Infusion Centers (POICs): A 2-Year Retrospective Multicenter Analysis
Outpatient Treatment and Recurrence of Prosthetic Joint Infection (PJI) Treated in Infectious Disease (ID) Physician Office Infusion Centers (POICs): A 2-Year Retrospective Multicenter Analysis
Presented on November 26, 2018 Authors: Brian S. Metzger, MD, MPH - Austin Infectious Disease Consultants, Austin, TX John S. Adams, MD, FIDSA, FSHEA - Knoxville Infectious Disease Consultants, P.C., Knoxville, TN Jorge R. Bernett, MD - Infectious Disease Doctors...
Real-World Experience of Vedolizumab in Pediatric Inflammatory Bowel Disease
Real-World Experience of Vedolizumab in Pediatric Inflammatory Bowel Disease
Presented on October 5, 2018 Authors: Annette E. Whitney, MD - Digestive Health Associates of Texas, Dallas, TX; Harry E. Sarles, Jr., MD, FACG - DHAT Research Institute, Richardson, TX Claudia P. Schroeder, PharmD, PhD - Healix Infusion Therapy, Sugar Land, TX...
Safety and Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Aged Population
Safety and Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Aged Population
Presented on October 4, 2017 Authors: Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Inc., Sugar Land, TX Richard M. Mandel, MD, FIDSA - University of Arizona College of Medicine, Tucson, AZ Ramesh V. Nathan, MD, FIDSA - Mazur, Statner, Dutta, Nathan, PC,...
Phase II and Phase III Studies
Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in Multiple Sclerosis and Intestinal Bowel Disease.
For information on partnering with Healix on a study, please contact us.